Lack of Racial Disparities in Cangrelor Therapy in Patients Presenting With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

IF 1.9 3区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Catheterization and Cardiovascular Interventions Pub Date : 2025-02-05 DOI:10.1002/ccd.31442

Waiel Abusnina, Kalyan R. Chitturi, Abhishek Chaturvedi, Lior Lupu, Dan Haberman, Matteo Cellamare, Vaishnavi Sawant, Cheng Zhang, Itsik Ben-Dor, Lowell F. Satler, Hayder D. Hashim, Brian C. Case, Ron Waksman

{"title":"Lack of Racial Disparities in Cangrelor Therapy in Patients Presenting With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention","authors":"Waiel Abusnina, Kalyan R. Chitturi, Abhishek Chaturvedi, Lior Lupu, Dan Haberman, Matteo Cellamare, Vaishnavi Sawant, Cheng Zhang, Itsik Ben-Dor, Lowell F. Satler, Hayder D. Hashim, Brian C. Case, Ron Waksman","doi":"10.1002/ccd.31442","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Cangrelor is an intravenous P2Y12 receptor antagonist that exerts rapid and potent antiplatelet effects. It is associated with a reduction in the indcidence of ischemic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>The aim of our study was to investigate the racial disparities and their impact on outcomes among patients with ACS who were treated with cangrelor during PCI.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We reviewed the data of patients with ACS who were treated with cangrelor during PCI at our center from 2018 to 2023 and divided between African American (AA) and Caucasian patients. The primary safety outcome was in-hospital thrombolysis in myocardial infarction (TIMI) major bleeding. The primary efficacy outcome was in-hospital major adverse cardiac events (MACE), defined as a composite of cardiac death, MI, or stroke. Multivariate regression analysis was performed to assess the primary outcomes after controlling for differences in baseline characteristics.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The study included 1181 patients who received cangrelor during PCI for ACS, including 616 AA and 565 Caucasian patients. AA patients were significantly younger (61 ± 13 vs. 64 ± 12 years; <i>p</i> < 0.001) and had higher rates of hypertension, diabetes mellitus, and end-stage renal disease requiring dialysis. There were no significant differences between AA and Caucasian patients regarding in-hospital TIMI major bleeding (odds ratio [OR]: 0.55; 95% confidence interval [CI]: 0.16–1.88<i>; p</i> = 0.343) and in-hospital MACE (OR: 1.82; 95% CI: 0.71–4.69<i>; p</i> = 0.212) after controlling for relevant baseline differences.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>No racial disparities were observed with regard to the administration of cangrelor during PCI in patients presenting with ACS, and cangrelor was not associated with increased bleeding for AA patients as compared to Caucasian patients.</p>\n </section>\n </div>","PeriodicalId":9650,"journal":{"name":"Catheterization and Cardiovascular Interventions","volume":"105 5","pages":"1188-1195"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Catheterization and Cardiovascular Interventions","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ccd.31442","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cangrelor is an intravenous P2Y12 receptor antagonist that exerts rapid and potent antiplatelet effects. It is associated with a reduction in the indcidence of ischemic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).

Aims

The aim of our study was to investigate the racial disparities and their impact on outcomes among patients with ACS who were treated with cangrelor during PCI.

Methods

We reviewed the data of patients with ACS who were treated with cangrelor during PCI at our center from 2018 to 2023 and divided between African American (AA) and Caucasian patients. The primary safety outcome was in-hospital thrombolysis in myocardial infarction (TIMI) major bleeding. The primary efficacy outcome was in-hospital major adverse cardiac events (MACE), defined as a composite of cardiac death, MI, or stroke. Multivariate regression analysis was performed to assess the primary outcomes after controlling for differences in baseline characteristics.

Results

The study included 1181 patients who received cangrelor during PCI for ACS, including 616 AA and 565 Caucasian patients. AA patients were significantly younger (61 ± 13 vs. 64 ± 12 years; p < 0.001) and had higher rates of hypertension, diabetes mellitus, and end-stage renal disease requiring dialysis. There were no significant differences between AA and Caucasian patients regarding in-hospital TIMI major bleeding (odds ratio [OR]: 0.55; 95% confidence interval [CI]: 0.16–1.88; p = 0.343) and in-hospital MACE (OR: 1.82; 95% CI: 0.71–4.69; p = 0.212) after controlling for relevant baseline differences.

Conclusion

No racial disparities were observed with regard to the administration of cangrelor during PCI in patients presenting with ACS, and cangrelor was not associated with increased bleeding for AA patients as compared to Caucasian patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

经皮冠状动脉介入治疗急性冠状动脉综合征患者的康瑞洛治疗缺乏种族差异。

背景：canrelor是一种静脉注射P2Y12受体拮抗剂，具有快速有效的抗血小板作用。它与急性冠脉综合征（ACS）患者经皮冠状动脉介入治疗（PCI）缺血性事件发生率的降低有关。目的：我们研究的目的是调查ACS患者在PCI期间接受康格乐治疗的种族差异及其对预后的影响。方法：我们回顾了2018年至2023年在我中心PCI期间接受康瑞洛治疗的ACS患者的数据，并将其分为非裔美国人（AA）和高加索人（Caucasian）。主要安全终点是院内溶栓治疗心肌梗死（TIMI）大出血。主要疗效终点是院内主要心脏不良事件（MACE），定义为心源性死亡、心肌梗死或中风的复合。在控制基线特征差异后，进行多变量回归分析以评估主要结果。结果：本研究纳入1181例在ACS PCI治疗期间接受康瑞洛治疗的患者，其中AA患者616例，高加索患者565例。AA患者明显年轻化(61±13岁∶64±12岁；结论：在ACS患者PCI治疗期间，canrelor的使用没有种族差异，与高加索患者相比，canrelor与AA患者出血增加无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Catheterization and Cardiovascular Interventions 医学-心血管系统

CiteScore

5.40

自引率

8.70%

发文量

419

审稿时长

2 months

期刊介绍： Catheterization and Cardiovascular Interventions is an international journal covering the broad field of cardiovascular diseases. Subject material includes basic and clinical information that is derived from or related to invasive and interventional coronary or peripheral vascular techniques. The journal focuses on material that will be of immediate practical value to physicians providing patient care in the clinical laboratory setting. To accomplish this, the journal publishes Preliminary Reports and Work In Progress articles that complement the traditional Original Studies, Case Reports, and Comprehensive Reviews. Perspective and insight concerning controversial subjects and evolving technologies are provided regularly through Editorial Commentaries furnished by members of the Editorial Board and other experts. Articles are subject to double-blind peer review and complete editorial evaluation prior to any decision regarding acceptability.